Market research
CYCN Cyclerion Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- 1.75
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US23255M2044
- Market cap
- 17M
- P/E ratio
- Not available
- Analyst target
- 8
- Dividend yield
- Not available
- Beta
- 1.75
About
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CYCN discussion.
5 years, 4 months ago
Cyclerion Therapeutics, Inc is currently in a long term uptrend where the price is trading 7.5% above its 200 day moving average.
From a valuation standpoint, the stock is 97.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 39.2.
Cyclerion Therapeutics, Inc's total revenue sank by 91.0% to $133K since the same quarter in the previous year.
Its net income has increased by 99.9% to $-19K since the same quarter in the previous year.
Finally, its free cash flow grew by 37.0% to $-14M since the same quarter in the previous year.
Based on the above factors, Cyclerion Therapeutics, Inc gets an overall score of 4/5.